Global Cardiovascular Drugs Market Report (2021 to 2030) - COVID-19 Impact and Recovery - ResearchAndMarkets.com

The "Cardiovascular Drugs Global Market Report 2021: COVID-19 Impact and Recovery to 2030" report has been added to ResearchAndMarkets.com's offering.

This report provides strategists, marketers and senior management with the critical information they need to assess the global cardiovascular drugs market as it emerges from the COVID-19 shut down.

The global cardiovascular drugs market is expected to grow from $87.79 billion in 2020 to $92.41 billion in 2021 at a compound annual growth rate (CAGR) of 5.3%. The growth is mainly due to the companies rearranging their operations and recovering from the COVID-19 impact, which had earlier led to restrictive containment measures involving social distancing, remote working, and the closure of commercial activities that resulted in operational challenges. The market is expected to reach $107.77 billion in 2025 at a CAGR of 4%.

Companies Mentioned

• Merck & Co
• Sanofi S.A
• Pfizer Inc
• Bristol-Myers Squibb Company
• Novartis AG

Reasons to Purchase

• Gain a truly global perspective with the most comprehensive report available on this market covering 50+ geographies.
• Understand how the market is being affected by the coronavirus and how it is likely to emerge and grow as the impact of the virus abates.
• Create regional and country strategies on the basis of local data and analysis.
• Identify growth segments for investment.
• Outperform competitors using forecast data and the drivers and trends shaping the market.
• Understand customers based on the latest market research findings.
• Benchmark performance against key competitors.
• Utilize the relationships between key data sets for superior strategizing.
• Suitable for supporting your internal and external presentations with reliable high quality data and analysis

Asia Pacific was the largest region in the global cardiovascular drugs market, accounting for 40% of the market in 2020. North America was the second largest region accounting for 27% of the global cardiovascular drugs market. Africa was the smallest region in the global cardiovascular drugs market.

NOACs are gaining wider acceptance and are replacing traditionally used anti-coagulants such as Warfarin and Heparin. Anti-coagulants have long been used in prevention of thrombus formation in patients suffering with cardiovascular diseases. Use of NOACs makes it easier for patients to continue therapy post discharge as opposed to injections of Heparin and Warfarin which need medical assistance for administration. Some of the NOACs include Pradaxa (dabigatran etexilate) from Boehringer Ingelheim, Xarelto (rivaroxaban) from Janssen, and Eliquis (apixaban) from Bristol-Myers Squibb.

High costs associated with drugs is a major issue faced by citizens of many countries. Pressure to contain costs and demonstrate value is widespread. Political uncertainty and persistent economic stress in numerous countries are calling into question the sustainability of public health care funding. In less wealthy countries, lack of cost-effective drugs has influenced the health conditions of the population and has led to a low average life expectancy. As a result, in countries such as Chad, Macedonia, Serbia, the pharmaceutical companies are faced with the pressure of reducing the price of drugs. The high costs associated with drugs are putting pressure on the revenues of cardiovascular drugs manufacturers.

The rise in sedentary jobs, busy lifestyles and changing consumer preferences are affecting the disease profile of the world population, especially non-communicable diseases such as cancer, diabetes and cardiovascular diseases. Long working hours, less physical activity, and unhealthy eating and drinking habits are major causes of cardiovascular diseases including hypertension. According to the World Health Organization, chronic disease prevalence is expected to rise by 57% globally, by the year 2020. These factors are expected to increase the patient pool globally, thereby driving the cardiovascular drugs market during the forecast period.

Key Topics Covered:

1. Executive Summary

2. Report Structure

3. Cardiovascular Drugs Market Characteristics

4. Cardiovascular Drugs Market Product Analysis

5. Cardiovascular Drugs Market Supply Chain

5.1. Supply Chain

5.2. Distribution

5.3. End Customers

6. Cardiovascular Drugs Market Customer Information

6.1. Customer Preferences

6.2. End Use Market Size and Growth

7. Cardiovascular Drugs Market Trends and Strategies

8. Impact of COVID-19 on Cardiovascular Drugs

9. Cardiovascular Drugs Market Size and Growth

9.1. Market Size

9.2. Historic Market Growth, Value ($ Billion)

9.3. Forecast Market Growth, Value ($ Billion)

10. Cardiovascular Drugs Market Regional Analysis

10.1. Global Cardiovascular Drugs Market, 2020, by Region, Value ($ Billion)

10.2. Global Cardiovascular Drugs Market, 2015-2020, 2020-2025F, 2030F, Historic and Forecast, by Region

10.3. Global Cardiovascular Drugs Market, Growth and Market Share Comparison, by Region

11. Cardiovascular Drugs Market Segmentation

11.1. Global Cardiovascular Drugs Market, Segmentation by Type,

11.2. Global Cardiovascular Drugs Market, Segmentation by Distribution Channel

11.3. Global Cardiovascular Drugs Market, Segmentation by Route of Administration

11.4. Global Cardiovascular Drugs Market, Segmentation by Drug Classification

11.5. Global Cardiovascular Drugs Market, Segmentation by Mode of Purchase

12. Cardiovascular Drugs Market Metrics

12.1. Cardiovascular Drugs Market Size, Percentage of GDP, 2015-2025, Global

12.2. Per Capita Average Cardiovascular Drugs Market Expenditure, 2015-2025, Global

For more information about this report visit https://www.researchandmarkets.com/r/ihic5s

View source version on businesswire.com: https://www.businesswire.com/news/home/20210513005758/en/